Buy a few shares of AMBS under a dime.
Company has a second "orphan indication" for MANF in hand. The speculation is that it's in the field of diabetes and Novartis and NovoNordisk are in development talks with the company currently.
Validation data from Becton Dickinson for "LymPro" which is the company's diagnostic test to detect early stage Alzheimer's is expected soon. $500,000,000 annual market.
Current fair value is .40. Due diligence.
Follow the company on Twitter: @AmarantusBio .... 8,472 followers
Deal with Becton Dickinson is in the works. Due diligence.
Most undervalued bio-tech.
Word is getting out. Strong accumulation continues.
One of the co-founders of Amgen and the former head of M & A for Novartis are two of the members on the company's advisory board.
Read the recen Yahoo news.
Follow the company on Twitter: @AmarantusBio .... 8,480 followers